Local vaccine trial sites are recruiting young children to test COVID-19 bivalent doses more than two months after the vaccines were authorized for use in adults, teens, and older children. Scientists will study the safety and efficacy of Pfizer-BioNTech’s bivalent shot in children as young as 6 months old. “The assessment is really to look at how it compares to the monovalent [vaccines] and to see if it makes a difference,” said Simon Li, associate professor of critical care at Rutgers Robert Wood Johnson Medical School and intensive care director for pediatrics at Bristol-Myers Squibb Children’s Hospital. To read the full story.